Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Search
Sore Mouth or Throat
Discover tips on how to take care of a sore mouth or throat from Taking Cancer On Through Flavour
Veganism
Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.
Roasted Eggplant Fan Video
Find out how this simple plant-based meal from Taking Cancer on Through Flavour and Taste Life are made
Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
TreatmentSequencing
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Streetvet: Free veterinary care
Learn more about StreetVet free veterinarian care for companion animals of the homeless
Contact BioXcellence
Contact BioXcellence
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Generalized pustular psoriasis is not ‘sensitive’ content
Learn about the impact that a lack of online visibility can have on people living with this chronic, inflammatory skin disease.